Education
About Us
Working with TipRanks
Follow Us
Madrigal (GB:0JXI)
:0JXI
0JXI Stock Chart & Stats
$455.01
$5.13(1.59%)
At close: 4:00 PM EST
$455.01
$5.13(1.59%)
Day’s Range― - ―
52-Week Range$264.12 - $465.09
Previous CloseN/A
Volume173.00
Average Volume (3M)38.00
Market Cap
$9.91B
Enterprise Value$9.54B
Total Cash (Recent Filing)$1.11B
Total Debt (Recent Filing)$1.08M
Price to Earnings (P/E)―
Beta0.49
Next Earnings
Mar 04, 2026EPS Estimate
-0.66Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.08
Shares Outstanding22,289,015
10 Day Avg. Volume23
30 Day Avg. Volume38
Financial Highlights & Ratios
PEG Ratio-1.47
Price to Book (P/B)8.70
Price to Sales (P/S)36.44
P/FCF Ratio-14.36
Enterprise Value/Market Cap0.96
Enterprise Value/Revenue12.89
Enterprise Value/Gross Profit13.55
Enterprise Value/Ebitda-34.36
Forecast
1Y Price Target
$519.64Price Target Upside14.20% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering17
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
EarningsRezdiffra's revenue of $287M significantly surpassed both analyst and market expectations.
Market ExpansionThe European Commission granted Rezdiffra conditional market authorization for treatment of MASH, which is a win for Madrigal’s expansion plans.
Product DemandRezdiffra is the first approved drug for MASH with early launch metrics indicating high demand and potential for upside from continued strong launch.
Bears Say
Competitive ChallengesCompetitive challenges are increasing, which may limit the upside potential for Madrigal's stock.
European Market ConcernsAnalysts believe the EU is unlikely to be a major growth driver for Madrigal, at least in the near term, due to slower European launch dynamics and pricing constraints.
Insurance And ReimbursementMany prescribers report issues with payers, which could impact the broader use of Rezdiffra.
Madrigal Pharmaceuticals News
0JXI FAQ
What was Madrigal’s price range in the past 12 months?
Madrigal lowest share price was $264.12 and its highest was $465.09 in the past 12 months.
What is Madrigal’s market cap?
Madrigal’s market cap is $9.91B.
When is Madrigal’s upcoming earnings report date?
Madrigal’s upcoming earnings report date is Mar 04, 2026 which is in 118 days.
How were Madrigal’s earnings last quarter?
Madrigal released its earnings results on Nov 04, 2025. The company reported -$5.08 earnings per share for the quarter, missing the consensus estimate of -$2.285 by -$2.795.
Is Madrigal overvalued?
According to Wall Street analysts Madrigal’s price is currently Undervalued.
Does Madrigal pay dividends?
Madrigal does not currently pay dividends.
What is Madrigal’s EPS estimate?
Madrigal’s EPS estimate is -0.66.
How many shares outstanding does Madrigal have?
Madrigal has 22,289,015 shares outstanding.
What happened to Madrigal’s price movement after its last earnings report?
Madrigal reported an EPS of -$5.08 in its last earnings report, missing expectations of -$2.285. Following the earnings report the stock price went up 11.024%.
Which hedge fund is a major shareholder of Madrigal?
Currently, no hedge funds are holding shares in GB:0JXI
Madrigal Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$519.64 (14.20% Upside)
$519.64 (14.20% Upside)
Blogger Sentiment
Bullish
GB:0JXI Sentiment 70%
Sector Average 71%
Sector Average 71%
Insider Transactions
Bought Shares
Worth $54.9M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
34.20%
12-Months-Change
Fundamentals
Return on Equity
-41.22%
Trailing 12-Months
Asset Growth
26.95%
Trailing 12-Months
Company Description
Madrigal
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.
0JXI Company Deck
0JXI Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call reflects a strong quarter for Madrigal Pharmaceuticals, driven by the successful launch of Rezdiffra and robust financial health. However, increased operating expenses and ongoing challenges with payer contracting highlight areas of concern. Additionally, competitive pressures from other entrants in the MASH market could impact future growth. Overall, the sentiment is cautiously optimistic.View all GB:0JXI earnings summaries0JXI Stock 12 Month Forecast
Average Price Target
$519.64
▲(14.20% Upside)
Technical Analysis
Corcept Therapeutics
―
Halozyme
―
BridgeBio Pharma
―
Revolution Medicines
―
Roivant Sciences
―
Options Prices
Currently, No data available
---